--- title: "Lyell Immunopharma | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 2 K" type: "News" locale: "en" url: "https://longbridge.com/en/news/285477237.md" datetime: "2026-05-07T03:13:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285477237.md) - [en](https://longbridge.com/en/news/285477237.md) - [zh-HK](https://longbridge.com/zh-HK/news/285477237.md) --- # Lyell Immunopharma | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 2 K Revenue: As of FY2026 Q1, the actual value is USD 2 K, missing the estimate of USD 4.4 K. EBIT: As of FY2026 Q1, the actual value is USD -26.35 M. #### Net Loss Lyell Immunopharma, Inc. reported a GAAP net loss of - $24.2 million for the first quarter ended March 31, 2026, which is an improvement compared to a net loss of - $52.2 million for the same period in 2025, representing a $28.0 million decrease in net loss primarily due to a $17.6 million gain on its Securities Purchase Agreement put/call asset. The non-GAAP net loss decreased by $8.5 million to - $37.8 million for the first quarter ended March 31, 2026, from - $46.3 million for the same period in 2025. #### Operating Expenses **Research and Development (R&D) Expenses**GAAP R&D expenses were $36.6 million for the first quarter ended March 31, 2026, down from $43.4 million for the same period in 2025, a decrease of $6.8 million. Non-GAAP R&D expenses were $34.4 million for the first quarter ended March 31, 2026, compared to $41.1 million for the same period in 2025. **General and Administrative (G&A) Expenses**GAAP G&A expenses were $9.6 million for the first quarter ended March 31, 2026, a decrease from $14.0 million for the same period in 2025. Non-GAAP G&A expenses were $7.5 million for the first quarter ended March 31, 2026, compared to $10.4 million for the same period in 2025. **Total Operating Expenses**Total operating expenses were $44.263 million for the first quarter ended March 31, 2026, compared to $57.374 million for the same period in 2025. #### Other Income/Loss Loss from operations was - $44.261 million for the first quarter ended March 31, 2026, compared to - $57.367 million for the same period in 2025. Net interest income was $2.194 million for Q1 2026, compared to $3.862 million for Q1 2025. Other income, net, was $17.914 million for Q1 2026, significantly up from $1.310 million for Q1 2025. Total other income, net, was $20.108 million for Q1 2026, compared to $5.172 million for Q1 2025. #### Balance Sheet Highlights Cash, cash equivalents, and marketable securities totaled $261.0 million as of March 31, 2026, an increase from $247.2 million as of December 31, 2025. Total assets were $350.626 million as of March 31, 2026, compared to $340.052 million as of December 31, 2025. Total stockholders’ equity was $273.665 million as of March 31, 2026, up from $248.202 million as of December 31, 2025. #### Capital Activities Lyell Immunopharma, Inc. closed the second $50 million tranche of its July 2025 equity private placement in March 2026, completing the total $100 million private placement, with shares sold at $25.61 per share. #### Outlook / Guidance Lyell Immunopharma, Inc. expects its current cash, cash equivalents, and marketable securities to provide a financial runway into the third quarter of 2027. Additional data for the PiNACLE pivotal clinical trial are expected in the second half of 2026, with pivotal data in mid-2027 and a Biologics License Application (BLA) submission to the FDA anticipated in 2027. For the LYL273 Phase 1 clinical trial, a data update focused on safety is expected in the first half of 2026, followed by a second data update including clinical outcomes in the second half of 2026. ### Related Stocks - [LYEL.US](https://longbridge.com/en/quote/LYEL.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [GDEV announces results for the first quarter of 2026 | GDEV Stock News](https://longbridge.com/en/news/286909689.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md) - [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md)